Phase4 Partners

Avocode, Inc. is a software company founded in 2013 and based in New York, New York. It specializes in file-sharing solutions that enhance collaboration between designers and developers. Avocode's primary products allow users to export and share various design elements from popular software such as Photoshop, Sketch, Figma, and Adobe XD. Its tools enable automatic generation of specifications, facilitate design reviews, and support direct editing of copy within design files. Additionally, Avocode provides an enterprise solution that synchronizes design and development workflows in a single platform, along with a Cloud API for accessing and extracting data from design files. The software serves to streamline the workflow in web and mobile projects, making it easier for teams to work together effectively.

Avocode, Inc. is a software company founded in 2013 and based in New York, New York. It specializes in file-sharing solutions that enhance collaboration between designers and developers. Avocode's primary products allow users to export and share various design elements from popular software such as Photoshop, Sketch, Figma, and Adobe XD. Its tools enable automatic generation of specifications, facilitate design reviews, and support direct editing of copy within design files. Additionally, Avocode provides an enterprise solution that synchronizes design and development workflows in a single platform, along with a Cloud API for accessing and extracting data from design files. The software serves to streamline the workflow in web and mobile projects, making it easier for teams to work together effectively.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.